Introduction: Obinutuzumab, a type II anti-CD20 monoclonal antibody used in the treatment of follicular lymphoma, is associated with a higher incidence of adverse events, including thrombocytopenia, compared to rituximab. We repo... ...

请注册登录后继续浏览